---
schema_version: "secwatch.filing_event.v1"
accession: "0001655759-25-000066"
form_type: "8-K"
ticker: "ARVN"
cik: "0001655759"
company_name: "ARVINAS, INC."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:07:13.447993+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arvinas Phase 1 data: ARV-102 achieves >50% central and >90% peripheral LRRK2 degradation

## Summary
- ARV-102 well tolerated in healthy volunteers; no serious adverse events in SAD (completed) or MAD (ongoing) cohorts.
- At single dose ≥60 mg and repeated ≥20 mg: >90% LRRK2 reduction in PBMCs and >50% in CSF.
- Median Tmax 6h, terminal half-life 73h; CSF exposure dose-dependent across SAD and MAD.
- Phase 1 trial in Parkinson's disease patients initiated Q4 2024; initial patient data expected in 2025.

## SEC filing metadata
- accession: 0001655759-25-000066
- form_type: 8-K
- ticker: ARVN
- cik: 0001655759
- company_name: ARVINAS, INC.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/0001655759-25-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1655759/000165575925000066/arvn-20250404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001655759-25-000066
- JSON: https://secwatch.observer/filing/0001655759-25-000066.json
- Plain text: https://secwatch.observer/filing/0001655759-25-000066.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.